Driscoll Childrens Hospital
Driscoll Childrens Hospital was paid $133.07M by Medicaid between Jan 2020 and Dec 2024, across 241 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 12% of everything it billed.
33Billing provider infoDRISCOLL CHILDRENS HOSPITAL
CORPUS CHRISTI, TX 78411
CORPUS CHRISTI, TX 78411
33aNPI1548286172assigned 07/15/2006
33bProvider typeSpeech-Language Pathologist
28Total paid$133.07M
24GClaims973,270
24DCodes billed241
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Speech-Language Pathologist providers in Texas
Rank by total paid#1 of 579
Median peer was paid$144K
This provider vs. median924×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 37,351 | $2.61M | |
| 2021 | 285,942 | $24.13M | |
| 2022 | 272,756 | $34.01M | |
| 2023 | 215,106 | $43.45M | |
| 2024incomplete | 162,115 | $28.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 59,455 | 56,183 | $15.44M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.3% | 25,287 | 23,865 | $11.00M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 8.1% | 60,111 | 57,765 | $10.83M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5.7% | 51,386 | 12,401 | $7.64M |
| 80053 | Comprehensive metabolic panel | 4.8% | 24,146 | 20,856 | $6.32M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 4.5% | 2,516 | 1,402 | $6.05M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 4.3% | 1,234 | 1,131 | $5.70M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 4.2% | 2,936 | 2,663 | $5.54M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.8% | 65,962 | 64,979 | $5.05M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.1% | 34,183 | 32,130 | $4.16M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 9,776 | 9,346 | $3.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 5,029 | 4,658 | $3.12M |
229 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 2,249 | $2.56M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 12,029 | $2.48M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 18,698 | $2.34M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.7% | 11,450 | $2.20M |
| 80050 | General health panel | 1.5% | 2,995 | $1.96M |
| 76825 | 1.4% | 657 | $1.86M | |
| 42830 | 1.2% | 404 | $1.59M | |
| 76770 | 1.2% | 2,593 | $1.58M | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.1% | 609 | $1.48M |
| 80061 | Lipid panel | 1.1% | 5,335 | $1.48M |
| 72082 | 1.0% | 2,515 | $1.36M | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 24,467 | $1.17M |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,961 | $1.13M |
| 93320 | <1% | 963 | $1.09M | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 10,192 | $1.07M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 31,464 | $1.03M |
| 84439 | <1% | 9,573 | $979K | |
| 81001 | <1% | 24,729 | $963K | |
| 93304 | <1% | 941 | $843K | |
| 94375 | <1% | 2,045 | $819K | |
| S8301 | Infection control supplies, not otherwise specified | <1% | 196,547 | $704K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 16,218 | $698K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,447 | $667K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,309 | $637K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,971 | $634K |
| 85027 | <1% | 11,138 | $591K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 313 | $567K |
| 67311 | <1% | 178 | $497K | |
| 93325 | <1% | 3,086 | $480K | |
| 88300 | <1% | 1,378 | $475K | |
| 85007 | <1% | 11,090 | $475K | |
| 93321 | <1% | 969 | $468K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,307 | $464K |
| 87631 | <1% | 7,044 | $460K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,012 | $442K |
| Q3014 | Telehealth originating site facility fee | <1% | 2,509 | $424K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,582 | $398K |
| 84100 | <1% | 3,471 | $379K | |
| 82570 | <1% | 2,710 | $371K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 9,054 | $319K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13,743 | $313K |
| 73100 | <1% | 1,426 | $298K | |
| 94060 | <1% | 520 | $288K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 63 | $286K |
| 83970 | <1% | 1,666 | $265K | |
| 73521 | <1% | 787 | $233K | |
| 76827 | <1% | 63 | $233K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 49 | $233K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 878 | $229K |
| 87807 | <1% | 3,026 | $228K | |
| 86140 | <1% | 7,018 | $222K | |
| 96130 | <1% | 613 | $217K | |
| 84156 | <1% | 1,462 | $215K | |
| 74018 | <1% | 3,112 | $210K | |
| 77073 | <1% | 513 | $190K | |
| 83735 | <1% | 2,856 | $168K | |
| 73070 | <1% | 904 | $166K | |
| 83516 | <1% | 1,047 | $165K | |
| 85652 | <1% | 2,154 | $159K | |
| 95782 | <1% | 52 | $151K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,700 | $149K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,177 | $147K |
| 73090 | <1% | 711 | $145K | |
| 82728 | <1% | 923 | $143K | |
| 73620 | <1% | 722 | $140K | |
| 73560 | <1% | 638 | $128K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 607 | $125K |
| 83525 | <1% | 1,081 | $124K | |
| 70486 | <1% | 49 | $123K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 79 | $114K |
| 83540 | <1% | 861 | $113K | |
| 83550 | <1% | 858 | $113K | |
| 81002 | <1% | 2,160 | $108K | |
| 81025 | <1% | 2,689 | $107K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 26 | $98K |
| 76000 | <1% | 230 | $90K | |
| 84550 | <1% | 703 | $89K | |
| 86161 | <1% | 704 | $89K | |
| 86160 | <1% | 713 | $88K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,064 | $86K |
| 99001 | <1% | 3,682 | $85K | |
| 82610 | <1% | 1,403 | $76K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 917 | $75K |
| 85046 | <1% | 1,479 | $70K | |
| 84436 | <1% | 481 | $70K | |
| 92567 | <1% | 939 | $67K | |
| 82784 | <1% | 980 | $67K | |
| 96112 | <1% | 149 | $63K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 146 | $59K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,406 | $56K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 12 | $55K |
| 86800 | <1% | 469 | $54K | |
| 86376 | <1% | 498 | $50K | |
| 73120 | <1% | 219 | $46K | |
| 73140 | <1% | 231 | $45K | |
| 86235 | <1% | 80 | $45K | |
| 83002 | <1% | 348 | $44K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,723 | $43K |
| 83001 | <1% | 315 | $38K | |
| 95811 | <1% | 14 | $36K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 146 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 140 | $35K |
| 80197 | <1% | 259 | $35K | |
| 87040 | <1% | 382 | $34K | |
| 72141 | <1% | 15 | $32K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 148 | $29K |
| 92582 | <1% | 86 | $26K | |
| 17106 | <1% | 24 | $26K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,656 | $26K |
| 77072 | <1% | 212 | $22K | |
| 92587 | <1% | 183 | $20K | |
| 92579 | <1% | 98 | $20K | |
| 82657 | <1% | 27 | $18K | |
| 93017 | <1% | 13 | $17K | |
| 95816 | <1% | 31 | $17K | |
| 73502 | <1% | 93 | $16K | |
| 82043 | <1% | 91 | $16K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 129 | $16K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 37 | $15K |
| 83690 | <1% | 436 | $15K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,602 | $15K |
| 69210 | <1% | 91 | $14K | |
| 99170 | <1% | 48 | $14K | |
| 82977 | <1% | 89 | $14K | |
| J3490 | Unclassified drugs | <1% | 1,824 | $14K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 103 | $14K |
| 86003 | <1% | 59 | $14K | |
| 96131 | <1% | 64 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,158 | $13K |
| 84403 | <1% | 41 | $12K | |
| 80047 | <1% | 48 | $12K | |
| 72170 | <1% | 53 | $12K | |
| 93308 | <1% | 13 | $11K | |
| 80177 | <1% | 77 | $10K | |
| 87077 | <1% | 89 | $9K | |
| 73630 | <1% | 43 | $9K | |
| 84146 | <1% | 68 | $8K | |
| 92526 | <1% | 119 | $8K | |
| 57452 | <1% | 30 | $8K | |
| 73610 | <1% | 50 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 745 | $8K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 61 | $7K |
| 92552 | <1% | 48 | $7K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 480 | $7K |
| 82465 | <1% | 59 | $7K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 524 | $7K |
| 73590 | <1% | 32 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 110 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 721 | $6K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,489 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 851 | $5K |
| 80074 | <1% | 14 | $5K | |
| 94664 | <1% | 5,518 | $5K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 834 | $5K |
| 83615 | <1% | 40 | $5K | |
| 87070 | <1% | 57 | $5K | |
| 86706 | <1% | 83 | $4K | |
| 96409 | <1% | 19 | $4K | |
| 82785 | <1% | 62 | $4K | |
| 84300 | <1% | 29 | $4K | |
| 86225 | <1% | 48 | $4K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 87 | $4K |
| 97162 | <1% | 12 | $4K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 163 | $3K |
| 82550 | <1% | 27 | $3K | |
| 84480 | <1% | 36 | $3K | |
| 95012 | <1% | 99 | $3K | |
| 84145 | <1% | 24 | $3K | |
| 83655 | <1% | 25 | $3K | |
| 82945 | <1% | 21 | $3K | |
| 89051 | <1% | 22 | $3K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 467 | $3K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 505 | $3K |
| 70360 | <1% | 12 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 353 | $2K |
| 88106 | <1% | 20 | $2K | |
| 87186 | <1% | 26 | $2K | |
| 86481 | <1% | 13 | $2K | |
| 82533 | <1% | 17 | $2K | |
| 82947 | <1% | 90 | $2K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 96 | $2K |
| 85014 | <1% | 58 | $2K | |
| 98960 | <1% | 268 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 27,376 | $1K |
| 84702 | <1% | 13 | $1K | |
| 86922 | <1% | 14 | $1K | |
| 86592 | <1% | 27 | $1K | |
| 86900 | <1% | 25 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $1K |
| 86885 | <1% | 12 | $1K | |
| 85018 | <1% | 58 | $961.12 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 213 | $933.96 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 718 | $922.18 |
| 97803 | <1% | 1,223 | $888.87 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 158 | $844.40 |
| 84157 | <1% | 21 | $828.60 | |
| 92504 | <1% | 22 | $812.16 | |
| 0071A | <1% | 42 | $759.97 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 253 | $753.91 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 280 | $740.52 |
| 99243 | <1% | 45 | $648.59 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 226 | $599.78 |
| 0072A | <1% | 18 | $542.69 | |
| 86308 | <1% | 42 | $523.27 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 101 | $502.67 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 4,260 | $444.05 |
| 73080 | <1% | 21 | $438.41 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 82 | $411.78 |
| 97802 | <1% | 930 | $376.73 | |
| 80320 | <1% | 13 | $375.45 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 52 | $313.80 |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 45 | $308.17 |
| 86901 | <1% | 12 | $285.92 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 53 | $280.63 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 51 | $189.90 |
| 36592 | <1% | 345 | $153.75 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 59 | $79.47 |
| 80143 | <1% | 13 | $71.91 | |
| 96127 | <1% | 2,379 | $55.17 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 71 | $48.55 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 160 | $9.60 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 51 | $0.00 |
| 91307 | 0% | 76 | $0.00 | |
| 36416 | 0% | 44 | $0.00 | |
| 99024 | 0% | 41 | $0.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 21 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 12 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 26 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAMON, ERIC (CHIEF FINANCIAL OFFICER)